William F. Benedict

13.6k total citations · 1 hit paper
172 papers, 10.8k citations indexed

About

William F. Benedict is a scholar working on Oncology, Molecular Biology and Ophthalmology. According to data from OpenAlex, William F. Benedict has authored 172 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 74 papers in Molecular Biology and 38 papers in Ophthalmology. Recurrent topics in William F. Benedict's work include Cancer-related Molecular Pathways (67 papers), Ocular Oncology and Treatments (38 papers) and Bladder and Urothelial Cancer Treatments (32 papers). William F. Benedict is often cited by papers focused on Cancer-related Molecular Pathways (67 papers), Ocular Oncology and Treatments (38 papers) and Bladder and Urothelial Cancer Treatments (32 papers). William F. Benedict collaborates with scholars based in United States, Spain and Japan. William F. Benedict's co-authors include A. Linn Murphree, Peter A. Jones, Hong Xu, Ashutosh Banerjee, Shi‐Xue Hu, Wen‐Hwa Lee, Walter E. Laug, Jin Qian, Steven H. Hinrichs and Colin P. Dinney and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

William F. Benedict

171 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structural Evidence for the Authenticity of the Human Retinoblastoma Gene

1987 651 citations William F. Benedict et al. profile →

Peers

Countries citing papers authored by William F. Benedict

Since Specialization

Citations

This map shows the geographic impact of William F. Benedict's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William F. Benedict with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William F. Benedict more than expected).

Fields of papers citing papers by William F. Benedict

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William F. Benedict. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William F. Benedict. The network helps show where William F. Benedict may publish in the future.

Co-authorship network of co-authors of William F. Benedict

This figure shows the co-authorship network connecting the top 25 collaborators of William F. Benedict. A scholar is included among the top collaborators of William F. Benedict based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William F. Benedict. William F. Benedict is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer 2016 ·Annals of Surgical Oncology ·Neema Navai, William F. Benedict, Guangcheng Zhang, (unknown), Nancy Ainslie, Jay B. Shah, H. Barton Grossman, Ashish M. Kamat, Colin P. Dinney	30
2	Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study 2014 ·Cancer Gene Therapy ·William F. Benedict, Myrna Fisher, (unknown), Zhi‐gang Yang, Mark F. Munsell, Colin P. Dinney	10
3	Direct cytotoxicity produced by adenoviral-mediated interferon α gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation 2011 ·Cancer Gene Therapy ·Zhaogang Yang, (unknown), Colin P. Dinney, William F. Benedict	10
4	Enhancement of intravesical delivery with Syn3 potentiates interferon-α2b gene therapy for superficial bladder cancer 2007 ·Cytokine & Growth Factor Reviews ·T. L. NAGABHUSHAN, Daniel C. Maneval, William F. Benedict, Shu-Fen Wen, Peter Ihnát, H Engler, Robert Connor	20
5	Adenoviral-mediated interferon α overcomes resistance to the interferon protein in various cancer types and has marked bystander effects 2006 ·Cancer Gene Therapy ·X. Zhang, Zhibo Yang, Lei Dong, Angela Papageorgiou, David J. McConkey, William F. Benedict	15
6	Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation 2005 ·Cancer Gene Therapy ·(unknown), Robert Connor, Faramarz Ashoori, Colin P. Dinney, Mark Munsell, (unknown), William F. Benedict	40
7	Focus on bladder cancer 2004 ·Cancer Cell ·Colin P. Dinney, David J. McConkey, Randall E. Millikan, Xifeng Wu, Menashe Bar‐Eli, Liana Adam, Ashish M. Kamat, Arlene O. Siefker‐Radtke, Tomasz Tuziak, Anita L. Sabichi, H. Barton Grossman, William F. Benedict, Bogdan Czerniak	230
8	Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens 2001 ·International Journal of Radiation OncologyBiologyPhysics ·Hideo Tokunaga, Shahrokh F. Shariat, (unknown), R. Malcolm Brown, Jain-Hua Zhou, William F. Benedict, Seth P. Lerner	23
9	p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy 2001 ·Urology ·Joel W. Slaton, William F. Benedict, Colin P. Dinney	40
10	Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis 2000 ·British Journal of Cancer ·Hisashi Shinohara, (unknown), Kiyotsugu Yoshikawa, Shujiro Yazumi, (unknown), Yoshio Yamaoka, Takuo Mizukami, Tomonori Yoshida, Shiro Akinaga, T Tamaoki, Hirotoshi Motoda, William F. Benedict, Rei Takahashi	6
11	Retinoblastoma protein expression and radiation response in muscle-invasive bladder cancer 1997 ·International Journal of Radiation OncologyBiologyPhysics ·Alan Pollack, Bogdan Czerniak, Gunar K. Zagars, (unknown), (unknown), Colin P. Dinney, (unknown), William F. Benedict	27
12	Loss of retinoblastoma gene function and heterozygosity at the RB locus in renal cortical neoplasms 1997 ·Human Pathology ·Syeling Lai, William F. Benedict, Susan A. Silver, Adel K. El‐Naggar	9
13	p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas 1996 ·Cancer ·Irma Gimenez‐Conti, A Collet, Héctor Lanfranchi, María E. Itoiz, Mario A. Luna, Hong‐Ji Xu, (unknown), William F. Benedict, Claudio J. Conti	59
14	The retinoblastoma gene is involved in malignant progression of astrocytomas 1994 ·Annals of Neurology ·John W. Henson, (unknown), (unknown), Andreas von Deimling, (unknown), Hong‐Ji Xu, William F. Benedict, David W. Yandell, David N. Louis	179
15	Chromosome 13 transfer provides evidence for regulation of RBI protein expression 1994 ·Genes Chromosomes and Cancer ·Michael J. Anderson, Clare L. Fasching, Eric J. Stanbridge, Hong‐Ji Xu, William F. Benedict	9
16	The Retinoblastoma Gene: Its Role in Human Malignancies 1990 ·Cancer Investigation ·William F. Benedict, Hong-Ji Xu, Rei Takahashi	12
17	Cyclophosphamide-induced oncogenic transformation, chromosomal breakage, and sister chromatid exchange following microsomal activation. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·William F. Benedict, Ashutosh Banerjee, Natarajan Venkatesan	41
18	Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Robert C. Seeger, Sylvia A. Rayner, (unknown), Helen Chung, Walter E. Laug, Harry B. Neustein, William F. Benedict	206
19	Oncogenic transformation of C3H/10T1/2 clone 8 mouse embryo cells by halogenated pyrimidine nucleosides. 1976 ·The Mouseion at the JAXlibrary (Jackson Laboratory) ·Peter A. Jones, William F. Benedict, Mary S. Baker, Sukdeb Mondal, Ulf R. Rapp, Charles Heidelberger	56
20	Chromosomal damage as a screen for carcinogenic/mutagenic potential of anticancer drugs 1976 ·Proceedings of the American Association for Cancer Research ·Ankona Banerjee, William F. Benedict	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact